132 related articles for article (PubMed ID: 12467216)
1. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.
Sale S; Sung R; Shen P; Yu K; Wang Y; Duran GE; Kim JH; Fojo T; Oefner PJ; Sikic BI
Mol Cancer Ther; 2002 Jan; 1(3):215-25. PubMed ID: 12467216
[TBL] [Abstract][Full Text] [Related]
2. beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues.
Gréen H; Rosenberg P; Söderkvist P; Horvath G; Peterson C
Cancer Lett; 2006 May; 236(1):148-54. PubMed ID: 16002208
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the beta-tubulin gene in lung cancer.
Tsurutani J; Komiya T; Uejima H; Tada H; Syunichi N; Oka M; Kohno S; Fukuoka M; Nakagawa K
Lung Cancer; 2002 Jan; 35(1):11-6. PubMed ID: 11750707
[TBL] [Abstract][Full Text] [Related]
4. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
Verdier-Pinard P; Wang F; Martello L; Burd B; Orr GA; Horwitz SB
Biochemistry; 2003 May; 42(18):5349-57. PubMed ID: 12731876
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.
Giannakakou P; Sackett DL; Kang YK; Zhan Z; Buters JT; Fojo T; Poruchynsky MS
J Biol Chem; 1997 Jul; 272(27):17118-25. PubMed ID: 9202030
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Monzó M; Rosell R; Sánchez JJ; Lee JS; O'Brate A; González-Larriba JL; Alberola V; Lorenzo JC; Núñez L; Ro JY; Martín C
J Clin Oncol; 1999 Jun; 17(6):1786-93. PubMed ID: 10561216
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.
Kelley MJ; Li S; Harpole DH
J Natl Cancer Inst; 2001 Dec; 93(24):1886-8. PubMed ID: 11752014
[No Abstract] [Full Text] [Related]
8. Mutational analysis of the class I beta-tubulin gene in human breast cancer.
Hasegawa S; Miyoshi Y; Egawa C; Ishitobi M; Tamaki Y; Monden M; Noguchi S
Int J Cancer; 2002 Sep; 101(1):46-51. PubMed ID: 12209587
[TBL] [Abstract][Full Text] [Related]
9. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.
Mesquita B; Veiga I; Pereira D; Tavares A; Pinto IM; Pinto C; Teixeira MR; Castedo S
BMC Cancer; 2005 Aug; 5():101. PubMed ID: 16095531
[TBL] [Abstract][Full Text] [Related]
10. Analysis of beta-tubulin gene alteration in human lung cancer cell lines.
Achiwa H; Sato S; Shimizu S; Maeda H; Niimi T; Takahashi T; Ueda R; Mitsudomi T
Cancer Lett; 2003 Nov; 201(2):211-6. PubMed ID: 14607336
[TBL] [Abstract][Full Text] [Related]
11. Absence of beta-tubulin gene mutation in gastric carcinoma.
Urano N; Fujiwara Y; Hasegawa S; Miyoshi Y; Noguchi S; Takiguchi S; Yasuda T; Yano M; Monden M
Gastric Cancer; 2003; 6(2):108-12. PubMed ID: 12861402
[TBL] [Abstract][Full Text] [Related]
12. New insights in beta-tubulin sequence analysis in non-small cell lung cancer.
de Castro J; Belda-Iniesta C; Cejas P; Casado E; Fresno Vara JA; Hardisson D; Sánchez JJ; Feliu J; Ordóñez A; Nistal M; González-Barón M
Lung Cancer; 2003 Jul; 41(1):41-8. PubMed ID: 12826311
[TBL] [Abstract][Full Text] [Related]
13. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A
Int J Cancer; 2007 May; 120(10):2078-85. PubMed ID: 17285590
[TBL] [Abstract][Full Text] [Related]
14. beta tubulin mutations are rare in human ovarian carcinoma.
Lamendola DE; Duan Z; Penson RT; Oliva E; Seiden MV
Anticancer Res; 2003; 23(1B):681-6. PubMed ID: 12680167
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
16. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.
Wang Y; O'Brate A; Zhou W; Giannakakou P
Cell Cycle; 2005 Dec; 4(12):1847-53. PubMed ID: 16294009
[TBL] [Abstract][Full Text] [Related]
17. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
18. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
Kavallaris M; Kuo DY; Burkhart CA; Regl DL; Norris MD; Haber M; Horwitz SB
J Clin Invest; 1997 Sep; 100(5):1282-93. PubMed ID: 9276747
[TBL] [Abstract][Full Text] [Related]
19. Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer.
Maeno K; Ito K; Hama Y; Shingu K; Kimura M; Sano M; Nakagomi H; Tsuchiya S; Fujimori M
Cancer Lett; 2003 Jul; 198(1):89-97. PubMed ID: 12893435
[TBL] [Abstract][Full Text] [Related]
20. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]